MARKET

KURA

KURA

Kura Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.13
+0.39
+1.58%
Closed 16:00 05/11 EDT
OPEN
24.00
PREV CLOSE
24.74
HIGH
25.66
LOW
23.74
VOLUME
285.56K
TURNOVER
--
52 WEEK HIGH
43.00
52 WEEK LOW
13.86
MARKET CAP
1.67B
P/E (TTM)
-14.5546
1D
5D
1M
3M
1Y
5Y
Was The Smart Money Right About Piling Into Kura Oncology, Inc. (KURA)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the fourth qu...
Insider Monkey · 1d ago
DJ Kura Oncology, Inc. CEO Troy Wilson on Q1 2021 Results -- Earnings Call Transcript >KURA
Dow Jones · 2d ago
H.C. Wainwright Reiterates Their Buy Rating on Kura Oncology (KURA)
SmarterAnalyst · 4d ago
8-K: Kura Oncology, Inc.
(EDGAR Online via COMTEX) -- false 0001422143 0001422143 2021-05-06 2021-05-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 5d ago
Kura Oncology EPS misses by $0.04
Kura Oncology (KURA): Q1 GAAP EPS of -$0.46 misses by $0.04. $603.9 million in cash, cash equivalents and investments provide runway into 2024.Press Release
Seekingalpha · 5d ago
Kura Oncology Q1 EPS $(0.46) Misses $(0.42) Estimate
Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.42) by 9.52 percent. This is a 9.52 percent decrease over losses of $(0.42) per share from the
Benzinga · 5d ago
10-Q: KURA ONCOLOGY, INC.
(EDGAR Online via COMTEX) -- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and...
Edgar Online - (EDG = 10Q, 10K) · 5d ago
Kura Oncology Reports First Quarter 2021 Financial Results
SAN DIEGO, May 06, May 06, 2021 (GLOBE NEWSWIRE via COMTEX) -- - Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable...
GlobeNewswire · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KURA. Analyze the recent business situations of Kura Oncology through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KURA stock price target is 43.29 with a high estimate of 53.00 and a low estimate of 38.00.
EPS
Institutional Holdings
Institutions: 246
Institutional Holdings: 66.80M
% Owned: 100.80%
Shares Outstanding: 66.27M
TypeInstitutionsShares
Increased
77
13.59M
New
51
7.14M
Decreased
55
6.82M
Sold Out
15
2.08M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.34%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/President/Chief Executive Officer/Director
Troy Wilson
Chief Financial Officer
Marc Grasso
Chief Operating Officer
Kathleen Ford
Other
Stephen Dale
Chief Compliance Officer/Secretary
Obsolete34418489538 Obsolete34418489538
Other
Kirsten Flowers
Other
Bridget Martell
Secretary
James Basta
Lead Director/Independent Director
faheem Hasnain
Lead Director/Independent Director
Faheem Hasnain
Independent Director
Robert Hoffman
Independent Director
Thomas Malley
Independent Director
Diane Parks
Independent Director
Steven Stein
Independent Director
Mary Szela
No Data
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.

Webull offers kinds of Kura Oncology Inc stock information, including NASDAQ:KURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KURA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KURA stock methods without spending real money on the virtual paper trading platform.